These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 28124932)

  • 21. [Systolic blood pressure targets].
    Souček M
    Vnitr Lek; 2016; 62(7-8):635-9. PubMed ID: 27627090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of achieved systolic blood pressure on renal function in hypertensive patients.
    Okin PM; Kjeldsen SE; Devereux RB
    Eur Heart J Qual Care Clin Outcomes; 2016 Oct; 2(4):271-276. PubMed ID: 29474712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypertension control and antihypertensive therapy in patients with chronic kidney disease.
    Unni S; White K; Goodman M; Ye X; Mavros P; Bash LD; Brixner D
    Am J Hypertens; 2015 Jun; 28(6):814-22. PubMed ID: 25421796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimated glomerular filtration rate and the risk-benefit profile of intensive blood pressure control amongst nondiabetic patients: a post hoc analysis of a randomized clinical trial.
    Obi Y; Kalantar-Zadeh K; Shintani A; Kovesdy CP; Hamano T
    J Intern Med; 2018 Mar; 283(3):314-327. PubMed ID: 29044764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Baseline Diastolic Blood Pressure and Cardiovascular Outcomes in SPRINT Participants with Chronic Kidney Disease.
    Chang TI; Wei G; Boucher R; Kramer H; Chertow GM; Cheung AK; Greene T; Whelton PK; Beddhu S
    Kidney360; 2020 May; 1(5):368-375. PubMed ID: 35369376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of home blood pressure control on renal and cardiovascular outcomes in elderly patients with chronic kidney disease.
    Okada T; Nakao T; Matsumoto H; Nagaoka Y; Tomaru R; Iwasawa H; Wada T
    Hypertens Res; 2009 Dec; 32(12):1123-9. PubMed ID: 19816503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blood Pressure Goals in Patients with CKD: A Review of Evidence and Guidelines.
    Chang AR; Lóser M; Malhotra R; Appel LJ
    Clin J Am Soc Nephrol; 2019 Jan; 14(1):161-169. PubMed ID: 30455322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term visit-to-visit office blood pressure variability increases the risk of adverse cardiovascular outcomes in patients with chronic kidney disease.
    Mallamaci F; Minutolo R; Leonardis D; D'Arrigo G; Tripepi G; Rapisarda F; Cicchetti T; Maimone I; Enia G; Postorino M; Santoro D; Fuiano G; De Nicola L; Conte G; Zoccali C
    Kidney Int; 2013 Aug; 84(2):381-9. PubMed ID: 23615498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BP Reduction, Kidney Function Decline, and Cardiovascular Events in Patients without CKD.
    Magriço R; Bigotte Vieira M; Viegas Dias C; Leitão L; Neves JS
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):73-80. PubMed ID: 29101186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generalizability of SPRINT Results to the U.S. Adult Population.
    Bress AP; Tanner RM; Hess R; Colantonio LD; Shimbo D; Muntner P
    J Am Coll Cardiol; 2016 Feb; 67(5):463-72. PubMed ID: 26562046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Personalizing the Intensity of Blood Pressure Control: Modeling the Heterogeneity of Risks and Benefits From SPRINT (Systolic Blood Pressure Intervention Trial).
    Patel KK; Arnold SV; Chan PS; Tang Y; Pokharel Y; Jones PG; Spertus JA
    Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28373269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Managing Hypertension in Patients with CKD: A Marathon, Not a SPRINT.
    Chertow GM; Beddhu S; Lewis JB; Toto RD; Cheung AK
    J Am Soc Nephrol; 2016 Jan; 27(1):40-3. PubMed ID: 26553785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The SPRINT study - the outcomes of the most important study over the recent period focused on hypertension].
    Souček M
    Vnitr Lek; 2016; 62(11):933-937. PubMed ID: 28128583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between blood pressure and kidney diseases in large randomized controlled trials: secondary analyses using SPRINT and ACCORD-BP trials.
    Wang L; Pezeshkian K; Rayamajhi S; Herzallah K; Al-Abcha A; Olomu A; Kelly-Blake K; Yu E; Wang DH
    J Hum Hypertens; 2021 Oct; 35(10):859-869. PubMed ID: 33093616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pros and Cons of Intensive Systolic Blood Pressure Lowering.
    Kramer H; Cooper R
    Curr Hypertens Rep; 2018 Mar; 20(2):16. PubMed ID: 29511979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of Hypertension: Which Goal for Which Patient?
    Jarraya F
    Adv Exp Med Biol; 2017; 956():117-127. PubMed ID: 27722961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On-Treatment Blood Pressure and Cardiovascular Outcomes in Older Adults With Isolated Systolic Hypertension.
    Yano Y; Rakugi H; Bakris GL; Lloyd-Jones DM; Oparil S; Saruta T; Shimada K; Matsuoka H; Imai Y; Ogihara T
    Hypertension; 2017 Feb; 69(2):220-227. PubMed ID: 28049699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [SPRINT study: far lower systolic blood pressure].
    Souček M; Řiháček I; Novák J
    Cas Lek Cesk; 2016; 155(4):9-12. PubMed ID: 27481195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blood Pressure Targets in CKD: Lessons Learned from SPRINT and Previous Observational Studies.
    Gosmanova EO; Kovesdy CP
    Curr Cardiol Rep; 2016 Sep; 18(9):88. PubMed ID: 27448402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Individual and Joint Effects of Pulse Pressure and Blood Pressure Treatment Intensity on Serious Adverse Events in the SPRINT Trial.
    Krishnaswami A; Kim DH; McCulloch CE; Forman DE; Maurer MS; Alexander KP; Rich MW
    Am J Med; 2018 Oct; 131(10):1220-1227.e1. PubMed ID: 29940151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.